Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for renal complications in type 2 diabetes
IRCT20260201068720N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of empagliflozin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Change in urinary albumin-to-creatinine ratio and Change in renal function. Started Feb 2026; status: completed.
02
Drugs
empagliflozin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20260201068720N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260201068720N1.